CETP and Hypertension: For example, torcetrapib (Pfizer, New York, NY, USA), an inhibitor of cholesteryl ester transfer protein (CETP), failed in the Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events (ILLUMINATE) trial for the increased risk of mortality and morbidity [7], due to the off-target effects of torcetrapib on hypertension [8].